MedCity News February 20, 2025
FibroGen secured regulatory approvals for roxadustat in China and Europe, but the FDA rejected the drug and asked for another clinical trial. By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication.
An anemia drug developed under an alliance between FibroGen and AstraZeneca will continue its commercialization in China fully in the hands of the pharmaceutical giant, which is buying the China business of its partner in a $160 million deal.
The agreement announced Thursday covers the rights to roxadustat in China, where the drug has become a top-selling product for treating anemia caused by chronic kidney disease. San Francisco-based FibroGen will use the cash...
Today's Sponsors
Today's Sponsor